KalVista Pharmaceuticals
KALV
KALV
130 hedge funds and large institutions have $467M invested in KalVista Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
130
Holders Change
+8
Holders Change %
+6.56%
% of All Funds
1.73%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
29
Increased
50
Reduced
29
Closed
19
Calls
$115K
Puts
$1.8M
Net Calls
-$1.69M
Net Calls Change
-$6.14M
Top Buyers
1 |
OCA
Octagon Capital Advisors
New York
|
+$11.6M |
2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$10.2M |
3 |
SC
Stempoint Capital
New York
|
+$8.41M |
4 |
VPC
Vestal Point Capital
New York
|
+$6.52M |
5 |
SCM
Suvretta Capital Management
New York
|
+$5.94M |
Top Sellers
1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$10.4M |
2 |
![]()
Adage Capital Partners
Boston,
Massachusetts
|
-$9.48M |
3 |
FTM
First Turn Management
Del Mar,
California
|
-$4.11M |
4 |
BlackRock
New York
|
-$1.68M |
5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$858K |